210 related articles for article (PubMed ID: 19391661)
1. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.
Vance GH; Barry TS; Bloom KJ; Fitzgibbons PL; Hicks DG; Jenkins RB; Persons DL; Tubbs RR; Hammond ME;
Arch Pathol Lab Med; 2009 Apr; 133(4):611-2. PubMed ID: 19391661
[TBL] [Abstract][Full Text] [Related]
2. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
[TBL] [Abstract][Full Text] [Related]
3. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
[TBL] [Abstract][Full Text] [Related]
4. Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity.
Allison KH; Dintzis SM; Schmidt RA
Am J Clin Pathol; 2011 Dec; 136(6):864-71. PubMed ID: 22095371
[TBL] [Abstract][Full Text] [Related]
5. Genetic heterogeneity in HER2 testing may influence therapy eligibility.
Bernasconi B; Chiaravalli AM; Finzi G; Milani K; Tibiletti MG
Breast Cancer Res Treat; 2012 May; 133(1):161-8. PubMed ID: 21901388
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.
Seol H; Lee HJ; Choi Y; Lee HE; Kim YJ; Kim JH; Kang E; Kim SW; Park SY
Mod Pathol; 2012 Jul; 25(7):938-48. PubMed ID: 22388760
[TBL] [Abstract][Full Text] [Related]
7. HER2 genetic heterogeneity in breast carcinoma.
Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
J Clin Pathol; 2011 Dec; 64(12):1112-6. PubMed ID: 22011446
[TBL] [Abstract][Full Text] [Related]
8. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
9. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
[TBL] [Abstract][Full Text] [Related]
11. [Intratumoral heterogeneity of HER2 status in breast carcinoma].
Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
Pathologe; 2010 Oct; 31 Suppl 2():292-5. PubMed ID: 20652266
[TBL] [Abstract][Full Text] [Related]
12. Pathologic Features and Clinical Implications of Breast Cancer With HER2 Intratumoral Genetic Heterogeneity.
Muller KE; Marotti JD; Tafe LJ
Am J Clin Pathol; 2019 Jun; 152(1):7-16. PubMed ID: 30892594
[TBL] [Abstract][Full Text] [Related]
13. Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients.
Otsuji K; Sasaki T; Tanaka A; Kunita A; Ikemura M; Matsusaka K; Tada K; Fukayama M; Seto Y
Breast Cancer Res Treat; 2017 Feb; 162(1):11-18. PubMed ID: 28039535
[TBL] [Abstract][Full Text] [Related]
14. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
Press MF; Sauter G; Buyse M; Fourmanoir H; Quinaux E; Tsao-Wei DD; Eiermann W; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Mackey JR; Bee V; Ma Y; Villalobos I; Campeau A; Mirlacher M; Lindsay MA; Slamon DJ
J Clin Oncol; 2016 Oct; 34(29):3518-3528. PubMed ID: 27573653
[TBL] [Abstract][Full Text] [Related]
15. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
16. HER2/neu gene amplification heterogeneity: the significance of cells with a 3:1 HER2/CEP17 ratio.
Layfield LJ; Schmidt RL
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):543-9. PubMed ID: 22495367
[TBL] [Abstract][Full Text] [Related]
17. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
[TBL] [Abstract][Full Text] [Related]
18. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
19. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
Shah MV; Wiktor AE; Meyer RG; Tenner KS; Ballman KV; Green SJ; Sukov WR; Ketterling RP; Perez EA; Jenkins RB
J Clin Oncol; 2016 Oct; 34(29):3502-3510. PubMed ID: 27458302
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
Hanna W; Nofech-Mozes S; Kahn HJ
Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
